Cognition rises after FDA backs late-stage trial plan for dementia drug
CGTX•Cognition Therapeutics said the FDA supported its plan for a nine-month late-stage study of zervimesine in people with dementia with Lewy bodies. Shares rose 7% premarket.
1. Trial plan supported
The study will compare a daily 100-milligram dose of zervimesine with placebo in people with mild-to-moderate dementia with Lewy bodies. Its main goal is to assess whether the drug reduces hallucinations and delusions; researchers will also assess patients’ ability to manage everyday activities.
